Endologix’s New IntuiTrak Endovascular AAA System Featured at International Congress
February 10 2009 - 11:36AM
Business Wire
Endologix, Inc. (NASDAQ: ELGX) today announced that a
live-case demonstration of its new IntuiTrak� Delivery System was
featured at the International Congress XXII Endovascular
Interventions conference in Scottsdale, Ariz. The procedure was
performed by Zvonimir Krajcer, MD, Co-director of the Peripheral
Vascular Disease Service at the Texas Heart Institute; Edward
Diethrich, M.D., Medical Director and Founder of the Arizona Heart
Institute; and Venkatesh G. Ramaiah, M.D., Vascular Surgeon at the
Arizona Heart Hospital. The endovascular AAA procedure was
successfully performed with a percutaneous approach and local
anesthesia.
IntuiTrak is an innovative system developed for the minimally
invasive delivery and deployment of the Powerlink� stent graft. The
device is currently in limited market release following U.S. Food
and Drug Administration approval in October 2008. IntuiTrak�s novel
design and deployment mechanism simplifies standard vascular
delivery of the Powerlink device and provides exceptional accuracy
and control. The low-profile delivery system features enhanced
flexibility, advanced hemostasis control and a hydrophilic coating
to facilitate smooth delivery, particularly in patients with
limited or difficult vascular access. Additionally, the delivery
catheter has an integrated sheath that minimizes the need to
exchange introducers, thereby having the potential to minimize
vessel trauma and reduce overall procedure time.
�Due to its low-profile and integrated sheath, IntuiTrak is
ideal for the percutaneous treatment of patients with AAA,� said
Dr. Krajcer. �I have used the new device in eight cases so far, and
have experienced 100% technical success and exceptional patient
outcomes.�
�The International Congress provides an excellent opportunity to
showcase IntuiTrak before a prestigious audience of physician
thought-leaders in the treatment of AAA,� said John McDermott,
Endologix President and CEO. �With the procedural advantages of
IntuiTrak, combined with the exceptional long-term clinical results
of the Powerlink device, we believe we are providing physicians
with a compelling technology to treat their AAA patients. We are
very encouraged by the physician feedback received to-date and are
on schedule for a full-market launch in the U.S. in the second
quarter of 2009.�
About International
Congress
In its 22nd year, International Congress on Endovascular
Interventions is a global educational forum where cardiovascular
specialists gather to discuss the newest developments in
endovascular interventions through peer-reviewed abstract
presentations and live-case demonstrations from Arizona Heart
Hospital, Arizona Heart Translational Research Center, and
locations around the globe. For additional information, please
visit www.endovascularcongress.org.
About Endologix
Endologix, Inc. develops and manufactures innovative therapies
for aortic disorders. The company�s IntuiTrak System is an
endovascular stent graft for treating abdominal aortic aneurysms
(AAA). AAA is a weakening of the wall of the aorta, the largest
artery in the body, resulting in a balloon-like enlargement. Once
AAA develops, it continues to enlarge and, if left untreated,
becomes increasingly susceptible to rupture. The overall patient
mortality rate for ruptured AAA is approximately 75%, making it a
leading cause of death in the U.S. Additional information can be
found on Endologix�s Web site at www.endologix.com.
Except for historical information
contained herein, this news release contains forward-looking
statements relating to the introduction of new products and
continuing clinical results obtained with the Powerlink System, the
accuracy of which are necessarily subject to risks and
uncertainties, all of which are difficult or impossible to predict
accurately and many of which are beyond the control of Endologix.
The Company undertakes no obligation to update its forward looking
statements. Please refer to the Company's Annual Report on Form
10-K for the year ended December 31, 2007, and the Company's other
filings with the Securities and Exchange Commission, for more
detailed information regarding these risks and other factors that
may cause actual results to differ materially from those expressed
or implied.
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jul 2023 to Jul 2024